Download a copy of the Sponsorship and exhibition prospectus
The WCoP Executive Committee working in partnership with the Population Approach Group of Australia and New Zealand (PAGANZ) are committed to delivering an outstanding WCoP in 2016 that will showcase application of pharmacometrics research and methodology. PAGANZ has a proven track record of teaching and research in
pharmacometrics with a strong application to clinical pharmacology. This experience will empower participants in WCoP 2016.
Your sponsorship contribution will help us advance pharmacometrics around the world. As you know, pharmacometrics allows us to directly connect scientific innovation with the patient and helps to bring better medicines to patients faster. As a sponsor of WCoP 2016, you would be demonstrating your commitment and your company’s commitment to this cause.
With over 200 direct international flights into Brisbane each week, access from Asia, Europe and USA is easy. Being the gateway to Australia’s most popular tourist region, we encourage you to bring your family and explore all that is on offer, from the Sunshine Coast to the north, to the Gold Coast to the south. Or perhaps travel further afield to some of the world’s most iconic natural attractions including 16 world heritage sites, the magical waters of the Great Barrier Reef, Kakadu National Park, and Australia’s most recognisable icon, Uluru rising out of the vast Red Centre – the choices are endless.
Thank you in advance for your thoughtful consideration.
WCoP 2016 Organising Committee Chair
Thank you to our sponsors:
|Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-eight medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy. In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit roche.com.|
|The School of Pharmacy at The University of Queensland, Brisbane has a very active and research focused Pharmacometrics group, which is focused primarily on establishing quantitative linkages between observed drug responses in the body, and the underlying pharmacological science. It is one of the foremost Pharmacometrics research institutions in Australasia. The School’s PM group has one of the longest histories in Australia dating back to the early 1990s with respect to population mixed-effects modelling. Members of the group are supervising numerous Australian and international research higher degree students, serve on TGA Advisory Committees on Prescription Medicines, acted as consultants to the international and national pharmaceutical industry, co-developed new software methodologies for PM research, established the Australian Centre for Paediatric Pharmacokinetics, and are members of the Australian Centre for Pharmacometrics which is an initiative of Therapeutic Innovation Australia. The group is highly active in supporting the international Pharmacometrics community organising and participating in the annual PAGANZ meeting and have been honoured by having Brisbane selected to host both the 2016 World Conference on Pharmacometrics, and the 2018 International Association of Therapeutic Drug Monitoring & Clinical Toxicology, both of which are major international meetings.|
|The Population Approach Group of Australia & New Zealand (PAGANZ, www.paganz.org) is an incorporated society founded on an interest in pharmacology and therapeutic applications using the population approach. Since 1999, an annual PAGANZ scientific meeting has been held in the Southern hemisphere, to encourage the use and development of pharmacometrics primarily in Australia and New Zealand. A key focus of this meeting is the application of population modelling and simulation techniques in the experimental, clinical and regulatory settings of clinical drug development. Meetings consist of hands-on workshops, given by world leaders in the field, followed by a scientific meeting giving researchers, particularly students, the opportunity to present and discuss work in a collegial and friendly environment. PAGANZ is proud to excel in teaching and support of research in this important area of pharmacology and drug development. PAGANZ is the organiser of the World Conference on Pharmacometrics 2016, Brisbane, Australia.|
|Model Answers increases the likelihood of successful drug development by applying modelling and advanced analytics to pharmacokinetic and pharmacodynamic data. With an expert team of staff that have first-hand experience in industry and FDA, you can rely upon Model Answers to help you make informative decisions using innovative model based methodologies. Our team of scientific staff implement a range of analyses to maximise knowledge from data collected during drug development, which includes population PK-PD analyses, paediatric trial design, clinical trial simulation, disease and mechanistic based model building. Our aim is to enhance the analysis, design and interpretation of your studies whilst providing a fast, efficient and high quality service.|
|Janssen Research & Development, LLC, a pharmaceutical company of Johnson & Johnson, develops treatments that improve the health and lifestyles of people worldwide. Research and development areas encompass novel targets in neurologic disorders, gastroenterology, oncology, infectious disease, diabetes, hematology, metabolic disorders, immunologic disorders, and reproductive medicine. Janssen Quantitative Sciences (QS) department contributes to the success of the Janssen R&D portfolio by applying quantitative methods, adaptive design principles and modeling and simulation approaches at all stages of development to enable the best possible decision at the earliest time-point in the most efficient manner. Partnering across R&D, QS brings the disciplines of statistics and clinical pharmacology together with modeling and simulation expertise to support the full drug development lifecycle from discovery through post-approval. Our ultimate goal is to help people live healthy lives. We have produced and marketed many first-in-class prescription medications and are poised to serve the broad needs of the healthcare market – from patients to practitioners, from clinics to hospitals. For more about Janssen R&D, LLC, visit www.janssenpharmaceuticalsinc.com.|
|The purpose of the International Society of Pharmacometrics (ISoP) is to promote and advance the discipline of Pharmacometrics and broaden its impact. We are individuals from around the globe from various backgrounds in pharmaceutics, engineering, statistics, and mathematics, who are passionate about advancing and promoting the field of Pharmacometrics.
The mission of the International Society of Pharmacometrics (ISoP) is the promotion and advancement of the discipline of pharmacometrics, through Integration, Innovation, and Impact: quantitative integration of multisource data and knowledge of clinical, biomedical, biological, engineering, statistical, and mathematical concepts, resulting in continuous methodological and technological innovation enhancing scientific understanding and knowledge, which in turn has an impact on discovery, research, development, approval, and utilization of new therapies.
Consistent with this mission, ISoP will:
|Occams provides high-quality strategic services to clients in the pharmaceutical industry. We derive our name from the principle known as Occam’s razor: when multiple explanations are equally capable of describing the outcome, the least complex solution is preferred. Make no mistake: we deliver complex state-of-the-art modelling, but our many years of experience in academia, regulatory agencies, industry, at CROs, and in providing consultancy services to the pharmaceutical industry have honed our ability to ask and answer the key questions in drug development clearly and efficiently without being distracted by side issues.|
|Pharmetheus offers consulting services with emphasis on the application of pharmacometric approaches to support drug development decisions. The company was founded in 2012 in Uppsala, Sweden, as a spin-off to the Pharmacometrics Research Group at Uppsala University. Pharmetheus provides strategic advice and technical expertise in most therapeutic areas and focuses on delivery of on-time, high quality work according to the latest regulatory guidelines. The team of consultants and advisors, with wide experience in the area of Model Based Drug Development, is dedicated to developing fit-for-purpose models and analyses to answer the research questions of our clients.|
|Clinical Network Services (CNS) is an integrated service group focused on product development headquartered in Australia with offices in New Zealand, the UK and the USA, who create value for small-medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner. CNS offers a unique service where it integrates BioDesk, an intelligent global product development and regulatory affairs consultancy, with our committed, highly experienced Australian/New Zealand clinical services and biometrics team. Further information about CNS and its intelligent development services can be found at www.clinical.net.au|